Baxter buys drug-delivery specialist for $380M; Analyst highlights pair of HepC drug developers;

@FierceBiotech: Report: Samsung to test genomic analysis service. Item | Follow @FierceBiotech

@JohnCFierce: FDA approves Firazyr (Shire) for HAE. News | Follow @JohnCFierce

@RyanMFierce: Furiex Pharmaceuticals snags $15M loan to advance pipeline, including antibiotic, IBC drug and statin Article | Follow @RyanMFierce

@MaureenFierce: HPV Vaccination Rates Low Among Teen Girls, CDC Reports. Story | Follow @MaureenFierce

> Baxter International said that it plans to buy drug-delivery specialist Baxa for $380 million in cash. Article

> In its financial report for the first half of 2011, Belgium-based Ablynx ($ABLX) said it had 7 of its Nanobody drugs, which are antibody-derived protein therapeutics, in Phase I and Phase II clinical trials. Item

> Robert W. Baird analyst Thomas Russo advises investors to take a look at two up-and-coming developers of hepatitis C treatments, Achillion Pharmaceuticals ($ACHN) and Inhibitex ($INHX). Report

Pharma News

@FiercePharma: Merck's discount offer to NICE wins OK for anti-TNF drug Simponi. Piece | Follow @FiercePharma

> Cipla eyes alliances to grow in emerging markets. Story

> 'Rogue' Seroquel found in OTC painkiller packs. More

> HPV vax uptake grows, but not fast enough for CDC. Article

And Finally... Amgen ($AMGN) is teaming up with actress Blythe Danner, who has postmenopausal osteoporosis, to boost awareness of the condition. Item

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.